Establishment Labs (NASDAQ:ESTA) Reaches New 12-Month Low – Here’s What Happened

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s share price hit a new 52-week low on Monday . The company traded as low as $29.87 and last traded at $31.03, with a volume of 104635 shares changing hands. The stock had previously closed at $32.05.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ESTA shares. Stephens upgraded Establishment Labs to a “strong-buy” rating in a research note on Monday, December 2nd. BTIG Research raised their target price on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of “Buy” and a consensus target price of $60.60.

Establishment Labs Stock Up 2.6 %

The company’s fifty day moving average price is $41.04 and its 200 day moving average price is $42.40. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.02. The company had revenue of $40.23 million during the quarter, compared to the consensus estimate of $40.60 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. During the same quarter in the previous year, the company posted ($1.12) earnings per share. Equities analysts forecast that Establishment Labs Holdings Inc. will post -2.42 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ESTA. Assenagon Asset Management S.A. acquired a new position in shares of Establishment Labs in the 4th quarter worth approximately $12,898,000. Millennium Management LLC increased its holdings in shares of Establishment Labs by 49.8% in the second quarter. Millennium Management LLC now owns 273,605 shares of the company’s stock valued at $12,433,000 after buying an additional 90,943 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Establishment Labs by 10.7% during the 3rd quarter. Rice Hall James & Associates LLC now owns 793,300 shares of the company’s stock valued at $34,326,000 after acquiring an additional 76,959 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Establishment Labs during the 3rd quarter worth $3,245,000. Finally, Bamco Inc. NY grew its holdings in shares of Establishment Labs by 13.6% in the 3rd quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock worth $21,176,000 after acquiring an additional 58,611 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.